Skip to content

A Clinical Study on Neurological Function Recovery in Nasopharyngeal Carcinoma Patients with Cranial Nerve Invasion in the Era of Immunotherapy

A Clinical Study on Neurological Function Recovery in Nasopharyngeal Carcinoma Patients with Cranial Nerve Invasion in the Era of Immunotherapy

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600123746
Enrollment
Unknown
Registered
2026-04-29
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal carcinoma (NPC)

Interventions

Observation Group:None

Sponsors

The First Affiliated Hospital of Xiamen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed nasopharyngeal carcinoma (NPC) by biopsy of nasopharyngeal mass. 2. Clinical stage T4 according to the 8th edition of the American Joint Committee on Cancer (AJCC) staging system, with concurrent cranial nerve involvement. 3. Planned to receive comprehensive treatment comprising immunotherapy combined with chemotherapy and radiotherapy. 4. Ability to comply with the prescribed examinations and willingness to undergo regular follow-up assessments.

Exclusion criteria

Exclusion criteria: 1. History of previous radiotherapy to the head and neck region. 2. Synchronous primary malignancy at other anatomical sites at the time of initial diagnosis. 3. Pre-existing diabetes mellitus, multiple sclerosis, Guillain-Barré syndrome, or other neurological disorders that may affect cranial nerve function. 4. History of neck trauma or surgical procedures resulting in cranial nerve damage.

Design outcomes

Primary

MeasureTime frame
Recovery Rate of Cranial Nerve Injury;overall survival, OS;Recovery Time of Cranial Nerve Function;

Secondary

MeasureTime frame
Progression-Free Survival;Locoregional relapse-free survival, LRFS;Distant metastasis-free survival,DMFS;

Countries

China

Contacts

Public ContactWu Sangang

The First Affiliated Hospital of Xiamen University

uno12345@163.com+86 592 2139531

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026